TY - JOUR
T1 - Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-ε-caprolactone based nanoparticles
AU - Jesus, Sandra
AU - Soares, Edna
AU - Costa, João
AU - Borchard, Gerrit
AU - Borges, Olga
N1 - Funding Information:
This work is funded by FEDER funds through the Operational Programme Competitiveness Factors – COMPETE and national funds by FCT – Foundation for Science and Technology under the project PTDC/SAU-FAR/115044/2009, fellowship DFRH – SFRH/BD/81350/2011 and strategic project UID/NEU/04539/2013. TEM microscopy analyses were performed at IBILI under FCT founding contract REDE/1510/RME/2005. Authors want to acknowledge Dr. Isabel Nunes and Dr. Luísa Cortes for technical expertise in flow cytometry and confocal microscopy, respectively.
Publisher Copyright:
© 2016 Elsevier B.V. All rights reserved.
PY - 2016/5/17
Y1 - 2016/5/17
N2 - Among new strategies to increase hepatitis B virus (HBV) vaccination, especially in developing countries, the development of self-administered vaccines is considered one of the most valuable. Nasal vaccination using polymeric nanoparticles (NPs) constitutes a valid approach to this issue. In detail, poly-ε-caprolactone (PCL)/chitosan NPs present advantages as a mucosal vaccine delivery system: The high resistance of PCL against degradation in biological fluids and the mucoadhesive and immunostimulatory properties of chitosan. In vitro studies revealed these NPs were retained in a mucus-secreting pulmonary epithelial cell line and were capable of entering into differentiated epithelial cells. The intranasal (IN) administration of 3 different doses of HBsAg (1.5 μg, 5 μg and 10 μg) adsorbed on a fixed amount of PCL/chitosan NPs (1614 μg) generated identical titers of serum anti-HBsAg IgG and anti-HBsAg sIgA in mice nasal secretions. Besides other factors, the NP surface characteristics, particularly, zeta potential differences among the administered formulations are believed to be implicated in the outcome of the immune response generated.
AB - Among new strategies to increase hepatitis B virus (HBV) vaccination, especially in developing countries, the development of self-administered vaccines is considered one of the most valuable. Nasal vaccination using polymeric nanoparticles (NPs) constitutes a valid approach to this issue. In detail, poly-ε-caprolactone (PCL)/chitosan NPs present advantages as a mucosal vaccine delivery system: The high resistance of PCL against degradation in biological fluids and the mucoadhesive and immunostimulatory properties of chitosan. In vitro studies revealed these NPs were retained in a mucus-secreting pulmonary epithelial cell line and were capable of entering into differentiated epithelial cells. The intranasal (IN) administration of 3 different doses of HBsAg (1.5 μg, 5 μg and 10 μg) adsorbed on a fixed amount of PCL/chitosan NPs (1614 μg) generated identical titers of serum anti-HBsAg IgG and anti-HBsAg sIgA in mice nasal secretions. Besides other factors, the NP surface characteristics, particularly, zeta potential differences among the administered formulations are believed to be implicated in the outcome of the immune response generated.
KW - Antigen delivery
KW - Dose-response
KW - Mucosal immunization
KW - Nanoparticles
KW - Poly-e-caprolactone (PCL)/chitosan
KW - Polymeric biomaterials
KW - Vaccine adjuvants
UR - http://www.scopus.com/inward/record.url?scp=84961918592&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2016.03.013
DO - 10.1016/j.ijpharm.2016.03.013
M3 - Article
C2 - 26976502
AN - SCOPUS:84961918592
SN - 0378-5173
VL - 504
SP - 59
EP - 69
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 1-2
ER -
